Telor Ophthalmic Pharmaceuticals Inc. ophthalmic news

TELR cut its workforce to eight from 26 in the wake of its announcement last month that Xarano failed to show statistical significance in preventing increased intraocular pressure after cataract surgery.

TELR, which had $7.4 million in cash as of June 30, declined to discuss its burn rate going forward. TELR lost $1.6 million (20 cents) in the second quarter ended June 30. ...